Preliminary investigations on acyl hydrazones bearing sulfonamides as inhibitors of the human Carbonic Anhydrase isoforms I, II, IX, and XII

Tarih
2025Yazar
Dinçel, Efe DoğukanKuran, Ebru Didem
Ece, Abdulilah
Başoğlu Ünal, Faika
Renzi, Gioele
Badii, Gloria
Carta, Fabrizio
Supuran, Cladiu T.
Ulusoy Güzeldemirci, Nuray
Üst veri
Tüm öğe kaydını gösterKünye
Dincel ED, Kuran ED, Ece A, Başoğlu-Ünal F, Renzi G, Badii G, Carta F, Supuran CT, Ulusoy-Güzeldemirci N. Preliminary Investigations on Acyl Hydrazones Bearing Sulfonamides as Inhibitors of the Human Carbonic Anhydrase Isoforms I, II, IX, and XII. Anticancer Agents Med Chem. 2025 Feb 25.Özet
Aim: The present study aims to identify the synthesis and structural characterization of acyl hydrazone- sulfonamide-containing compounds that were tested in vitro on human carbonic anhydrase (hCA) isoforms I, II, IX, and XII.
Methods: Herein, acyl hydrazone derivatives containing the primary sulfonamide moiety were synthesized via a three-step synthetic pathway starting from the commercially available 4-sulfamoyl benzoic acid. Structural characterizations of the final compounds were assessed through IR IR, 1H-NMR, 13C-NMR, and elemental analyses. The in vitro profiling activity of the final compounds on the Carbonic Anhydrases (CAs; EC 4.2.1.1) I, II, IX, and XII were performed by means of the stopped-flow technique and revealed nanomolar inhibitory potencies on the selected targets. Molecular docking and molecular dynamic simulations afforded a detailed understanding of the binding modes of the most effective compounds.
Results: We reported the synthesis and structural characterization of 25 acyl hydrazone-sulfonamide-containing compounds that were tested in vitro on the hCAs I, II, IX, and XII isoforms for their inhibitory features. Overall, all compounds showed nanomolar inhibition potencies on the panel of hCAs considered, and their binding modes were deciphered by means of in-silico studies. Molecular docking followed by MD simulations confirmed the stability of 4l-hCA I, 4n-hCA II, 4t-hCA II, 4v-hCA XII, and 4w-hCA XII complexes.
Conclusion: This study presents a deep understanding of the structural determinants influencing the affinity and selectivity of the designed compounds towards different hCAs, thus offering valuable insights for further optimization and development in the field.
Kaynak
Anti-Cancer Agents in Medicinal ChemistryBağlantı
https://pubmed.ncbi.nlm.nih.gov/40012289/https://www.benthamscience.com/journal/1
https://hdl.handle.net/20.500.12780/1155